14-day Premium Trial Subscription Sign Up For FreeGet Free

Weaker Stock
Today LIFE ranks #20294 as sell candidate. Get a Free Stock at Robinhood
Stronger Stock

aTyr Pharma Stock Forecast NASDAQ:LIFE

$5.65 (-4.72%)

Volume: 106k

Closed: Jan 26, 2022

Hollow Logo Score: -6.537

aTyr Pharma Stock Forecast

$5.65 (-4.72%)

Volume: 106k

Closed: Jan 26, 2022

Score Hollow Logo -6.537

aTyr Pharma Company Profile

3545 John Hopkins Court

San Diego CA 92121



Industry: Biotechnology

Sector: Healthcare

aTyr Pharma


aTyr Pharma, Inc., a biotherapeutics company, engages in the discovery and clinical development of Physiocrine-based therapeutics for patients suffering from severe and rare diseases. The company develops Resolaris, which is in Phase Ib/II clinical trials for treating adult patients with facioscapulohumeral muscular dystrophy (FSHD), a rare genetic myopathy with an immune component; patients with early onset FSHD; and adult patients with limb-girdle muscular dystrophy 2B or FSHD. In addition, the company is developing iMod.Fc, a preclinical immuno-modulatory domain program. The company was founded in 2005 and is headquartered in San Diego, California.

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE